Thomas Hank
Harvard University
CancerInternal medicineRadiologySurgeryOncologyResectionRetrospective cohort studyPathologicalAdjuvant therapyResection marginNeoadjuvant therapyPancreasContext (language use)Pancreatic cancerLymph nodePancreatic fistulaAdenocarcinomaPancreatic ductal adenocarcinomaCancer researchProportional hazards modelMedicineBiologyGastroenterology
Publications 58
#1S. Lesch (LMU: Ludwig Maximilian University of Munich)H-Index: 5
#2Viktoria Blumenberg (LMU: Ludwig Maximilian University of Munich)H-Index: 1
Last. Sebastian Kobold (LMU: Ludwig Maximilian University of Munich)H-Index: 24
view all 58 authors...
The efficacy of adoptive cell therapy for solid tumours is hampered by the poor accumulation of the transferred T cells in tumour tissue. Here, we show that forced expression of C-X-C chemokine receptor type 6 (whose ligand is highly expressed by human and murine pancreatic cancer cells and tumour-infiltrating immune cells) in antigen-specific T cells enhanced the recognition and lysis of pancreatic cancer cells and the efficacy of adoptive cell therapy for pancreatic cancer. In mice with subcut...
#1Thomas Hank (University Hospital Heidelberg)H-Index: 11
#2M.W. Büchler (University Hospital Heidelberg)
Last. John P. Neoptolemos (University Hospital Heidelberg)H-Index: 125
view all 3 authors...
There is increasing interest in the use of adjuvant treatment for pancreatic cancer since although postoperative mortality is much improved, median long-term survival is only on the order of 11–15 mo. Despite a proliferation of studies in advanced pancreatic cancer indicating a benefit for chemotherapy, there has only been one small randomized adjuvant trial. A combination of 5-fluorouracil, doxorubicin, and mitomycin-C demonstrated a significantly improved median survival (23 vs 11 mo in contro...
3 CitationsSource
#1Pei-Yun Tsai (Harvard University)H-Index: 2
#2Min-Sik Lee (Broad Institute)H-Index: 1
Last. Nada Y. Kalaany (Broad Institute)H-Index: 11
view all 19 authors...
Pancreatic ductal adenocarcinoma (PDA) is a lethal, therapy-resistant cancer that thrives in a highly desmoplastic, nutrient-deprived microenvironment. Several studies investigated the effects of depriving PDA of either glucose or glutamine alone. However, the consequences on PDA growth and metabolism of limiting both preferred nutrients have remained largely unknown. Here, we report the selection for clonal human PDA cells that survive and adapt to limiting levels of both glucose and glutamine....
1 CitationsSource
#1Thomas HankH-Index: 11
#2Ulf HinzH-Index: 64
Last. Oliver StrobelH-Index: 50
view all 15 authors...
Objective To develop and validate a pretreatment prognostic score in pancreatic cancer (PDAC). Background Pretreatment prognostication in PDAC is important for treatment decisions but remains challenging. Available prognostic tools are derived from selected cohorts of patients who underwent resection, excluding up to 20% of patients with exploration only, and do not adequately reflect the pretreatment scenario. Methods Patients undergoing surgery for PDAC in Heidelberg from 07/2006 to 06/2014 we...
#1J. Kaiser (University Hospital Heidelberg)H-Index: 4
#2Ulf Hinz (University Hospital Heidelberg)H-Index: 17
Last. Oliver Strobel (University Hospital Heidelberg)H-Index: 50
view all 9 authors...
INTRODUCTION Adenosquamous carcinoma of the pancreas (ASCP) is a rare subtype of pancreatic adenocarcinoma. The aim of this study was to investigate the characteristics and outcomes of ASCP in comparison to pancreatic ductal adenocarcinoma (PDAC). MATERIALS AND METHODS All patients with ASCP treated between December 2001 and December 2017 were identified from a prospective database. Clinicopathological and follow-up data were analyzed. A nested case-control-study with matched-pair analysis was p...
#1David J Birnbaum (AMU: Aix-Marseille University)H-Index: 1
#1David Jérémie Birnbaum (Harvard University)H-Index: 48
Last. Andrew S. Liss (Harvard University)H-Index: 20
view all 17 authors...
PURPOSE Pancreatic ductal adenocarcinoma (PDAC) lethality is multifactorial; although studies have identified transcriptional and genetic subsets of tumors with different prognostic significance, there is limited understanding of features associated with the minority of patients who have durable remission after surgical resection. In this study, we performed laser capture microdissection (LCM) of PDAC samples to define their cancer- and stroma-specific molecular subtypes and identify a prognosti...
#1Ulla Klaiber (Heidelberg University)H-Index: 15
#2Eva S. Schnaidt (Heidelberg University)H-Index: 1
Last. Thilo HackertH-Index: 57
view all 11 authors...
: MINI: We analyzed prognostic factors after neoadjuvant therapy and resection in 280 patients with initially unresectable pancreatic cancer-the largest single-center study reported. We found that preoperative CA 19-9 levels, lymph node status, presence of distant metastases, and vascular involvement were all independent overall survival predictors, but not resection margin status. OBJECTIVE: To evaluate the impact of clinical and pathological parameters, including resection margin (R) status, o...
23 CitationsSource
#1Thomas HankH-Index: 11
#2Ulf HinzH-Index: 17
Last. Oliver StrobelH-Index: 50
view all 16 authors...
#1K. Meisenbacher (Heidelberg University)H-Index: 5
#2Dittmar Böckler (Heidelberg University)H-Index: 53
Last. Moritz S. Bischoff (Heidelberg University)H-Index: 15
view all 5 authors...
OBJECTIVES Optimal treatment for patients with diseased proximal landing zones in acute/subacute Stanford type B dissection and intramural haematoma remains unclear. This study describes the preliminary outcomes of a localized endovascular treatment [spot-stent grafting (SSG)] of main entries/intramural blood pooling located downstream (aortic zones 4 and 5) using one single short device comprising diseased landing zones, looking particularly at the technical and morphological outcomes. METHODS ...
1 CitationsSource
#1Ilaria TrestiniH-Index: 7
#2Salvatore PaiellaH-Index: 23
Last. Michele MilellaH-Index: 50
view all 20 authors...